

## **Adherium to support Avillion sponsored clinical study in Mild Asthma**

**Melbourne, Australia – 2 June 2022:** Adherium (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces that it has been awarded the contract for the supply of the Hailie® solution to Avillion LLP, sponsor of a US-based clinical study in mild Asthma in partnership with AstraZeneca. Adherium announced in September 2021 that it had contracted with AstraZeneca for supply to this study, and this has now transitioned to the sponsor Avillion under its clinical co-development agreement with AstraZeneca.

Avillion is a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval. The upcoming clinical study is an expansion of the clinical co-development agreement with AstraZeneca for PT027, a potential first-in-class inhaled, fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), in the US. Positive results from previous trials of PT027 were presented at the American Thoracic Society 2022 International Conference in May.

Rick Legleiter, Adherium’s CEO commented “we are very pleased to be working with Avillion and AstraZeneca, supporting their clinical co-development agreement through the collection of objective clinical trial data using Adherium’s Hailie technology. This is an immediate example of our new strategic sales approach working with new customers while supporting current customers to grow revenue in this market segment. The use in a decentralised clinical study where patients are monitored remotely in real time has been successfully employed in many other clinical studies and validates our focus on providing the Hailie solution for real-world remote patient monitoring by healthcare providers. And, this work aligns with our go-to-market channel strategy for expanding with US remote monitoring companies, health systems, traditional payors, self-insured payors, and payviders.”

As previously announced, Adherium will be providing a bespoke version of its Hailie sensor and software to track the usage of the investigational inhaler medications via the study participants' phones. Manufacturing of the sensors is underway, and these and the software are expected to be supplied over Q2 and Q3 calendar 2022. Adherium confirms the contract revenue guidance of approximately US\$650,000, with the majority of this to be generated in Q3 calendar 2022 and further support services will be supplied over the course of the study's two-year duration. The contract with Avillion for the clinical study is on usual commercial terms.

### **About Avillion**

Avillion offers pharma partners an innovative model providing additional funding and clinical development expertise, to maximise the potential of new and existing assets. Avillion takes on the full clinical and regulatory risk, focusing on the speed and quality of trial execution. Typically supporting programs post proof-of-concept through to registration and with an agnostic approach to therapy area, Avillion prides itself in adding value around operational expertise while being backed by established life science investors.

For more information, please visit [www.avillionllp.com](http://www.avillionllp.com)

### **About Adherium (ASX: ADR)**

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK)



and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at [www.adherium.com](http://www.adherium.com)

This ASX announcement was approved and authorised for release by the Board of Adherium.

**Enquiries:** WE Communications  
WE-AUAdherium@we-worldwide.com